14.09.2026
Single-Use In Sterile Manufacturing: Where It Adds Flexibility
As outsourcing strategies evolve, drug developers are increasingly seeking manufacturing partners that can offer not only capacity, but also flexibility, speed, and risk mitigation. One of the most important enablers of this shift is the growing use of single-use systems (SUS) in sterile manufacturing.
At medac CDMO, we see firsthand how the choice between single-use and traditional stainless-steel technologies directly impacts production timelines, changeover efficiency, and contamination control. By sharing our perspective, we aim to provide a practical understanding of where single-use systems truly add value—and where their application should be carefully evaluated.
The Evolution of Single-Use Systems in Pharmaceutical Manufacturing
Single-use systems represent one of the most significant technological advances in modern pharmaceutical production. These systems, typically composed of disposable bags, mixing and filtration units, filling assemblies, tubing, and connectors, were first introduced in the 1980s, primarily at laboratory scale. At that time, stainless-steel equipment remained the undisputed industry standard for commercial manufacturing.
A turning point came with the rise of biologics. As therapies became more complex and pipelines more diverse, the need for flexible, adaptable manufacturing solutions increased. This shift accelerated the development and adoption of single-use technologies, transforming them from niche tools into essential components of modern production environments.
Driving Flexibility Through Faster Changeovers
One of the most immediate advantages of single-use systems lies in their ability to significantly reduce production changeover times. In traditional stainless-steel setups, each batch transition requires extensive cleaning and sterilization processes, followed by analytical verification before the equipment can be released for subsequent use. These steps are resource-intensive, time-consuming, and closely tied to the availability of purified water and steam.
Single-use systems eliminate much of this complexity. After each production run, the used components are simply removed and replaced with pre-sterilized, ready-to-use assemblies. This approach not only accelerates changeovers but also simplifies operational workflows. For CDMOs managing multiple products or smaller batch sizes, this increased agility can translate into shorter lead times and improved responsiveness to client needs.
Last but not least, a significant benefit is the reduction in the risk of cross-contamination between individual products. Each production cycle uses new, pre-sterilized components, eliminating the possibility of carrying over residues from the previous batch. This approach increases the safety of the manufacturing process and the quality of the final product. It also allows the production line to be quickly adapted for a different type of product.
Balancing Single-Use and Stainless Steel
Despite their advantages, single-use systems are not a universal solution. Conventional stainless-steel equipment continues to play a critical role in pharmaceutical manufacturing, particularly for large-scale production where long-term efficiency and sustainability are key considerations. These systems are robust, well-established, and capable of delivering high throughput when supported by properly validated cleaning and sterilization processes.
The choice between single-use and conventional technologies should therefore always be based on specific requirements for the type of product, production volume, and the degree of flexibility required in the production process.
Conclusion
As pharmaceutical pipelines become more diverse and increasingly focused on complex and targeted therapies, manufacturing systems must evolve accordingly. Single-use technologies offer clear advantages in flexibility, speed, and contamination control, making them particularly well-suited for multiproduct environments and smaller-scale production.
Our approach is to apply these technologies where they deliver the greatest value—aligning manufacturing design with the specific needs of each product. By combining experience with both single-use and conventional systems, we support our partners in navigating complexity, reducing risk, and building robust supply strategies. In an increasingly competitive and fast-moving landscape, this ability to align manufacturing with product and development realities is what ultimately enables therapies to reach patients safely and reliably.
At medac CDMO, we see firsthand how the choice between single-use and traditional stainless-steel technologies directly impacts production timelines, changeover efficiency, and contamination control. By sharing our perspective, we aim to provide a practical understanding of where single-use systems truly add value—and where their application should be carefully evaluated.
The Evolution of Single-Use Systems in Pharmaceutical Manufacturing
Single-use systems represent one of the most significant technological advances in modern pharmaceutical production. These systems, typically composed of disposable bags, mixing and filtration units, filling assemblies, tubing, and connectors, were first introduced in the 1980s, primarily at laboratory scale. At that time, stainless-steel equipment remained the undisputed industry standard for commercial manufacturing.
A turning point came with the rise of biologics. As therapies became more complex and pipelines more diverse, the need for flexible, adaptable manufacturing solutions increased. This shift accelerated the development and adoption of single-use technologies, transforming them from niche tools into essential components of modern production environments.
Driving Flexibility Through Faster Changeovers
One of the most immediate advantages of single-use systems lies in their ability to significantly reduce production changeover times. In traditional stainless-steel setups, each batch transition requires extensive cleaning and sterilization processes, followed by analytical verification before the equipment can be released for subsequent use. These steps are resource-intensive, time-consuming, and closely tied to the availability of purified water and steam.
Single-use systems eliminate much of this complexity. After each production run, the used components are simply removed and replaced with pre-sterilized, ready-to-use assemblies. This approach not only accelerates changeovers but also simplifies operational workflows. For CDMOs managing multiple products or smaller batch sizes, this increased agility can translate into shorter lead times and improved responsiveness to client needs.
Last but not least, a significant benefit is the reduction in the risk of cross-contamination between individual products. Each production cycle uses new, pre-sterilized components, eliminating the possibility of carrying over residues from the previous batch. This approach increases the safety of the manufacturing process and the quality of the final product. It also allows the production line to be quickly adapted for a different type of product.
Balancing Single-Use and Stainless Steel
Despite their advantages, single-use systems are not a universal solution. Conventional stainless-steel equipment continues to play a critical role in pharmaceutical manufacturing, particularly for large-scale production where long-term efficiency and sustainability are key considerations. These systems are robust, well-established, and capable of delivering high throughput when supported by properly validated cleaning and sterilization processes.
The choice between single-use and conventional technologies should therefore always be based on specific requirements for the type of product, production volume, and the degree of flexibility required in the production process.
Conclusion
As pharmaceutical pipelines become more diverse and increasingly focused on complex and targeted therapies, manufacturing systems must evolve accordingly. Single-use technologies offer clear advantages in flexibility, speed, and contamination control, making them particularly well-suited for multiproduct environments and smaller-scale production.
Our approach is to apply these technologies where they deliver the greatest value—aligning manufacturing design with the specific needs of each product. By combining experience with both single-use and conventional systems, we support our partners in navigating complexity, reducing risk, and building robust supply strategies. In an increasingly competitive and fast-moving landscape, this ability to align manufacturing with product and development realities is what ultimately enables therapies to reach patients safely and reliably.
